Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The answer marked is clearly "no" in report. Check otc
Thanks - couldn't find this out. So by 30th of this month is what we have as due date if I understand correctly
They have requested extension. Extension time is missing as well as reason given. Looks like some error when uploaded by OTC
Already NT 10Q was filed requesting extension on May 15. Form is not correctly uploaded by SEC, the attachment containing the reason is missing along with requested extension.
The last filing day was 45 days from end of quarter. Else they have file it with fine. Yield symbol is normal under such circumstances.
FDA doesn't approve homeopathic medicines in general because it's an alternative medicine system.
Agree. Now revenues on MJ leading are not going to show up until Q3-Q4.
After auditing dolomite reserves, we should have nice accumulation in assets - but I personally believe 1 billion $ - is little overrated even considering market values. When we see the financial report on July 15 for Q2 we would come to know. As to quarterly report, many investors had high expectation because of lots of back to back pr's, frankly not many realized all these would come into play in coming financial results. Over the next few weeks if we get more potential players as licensee for leasing, or any news should put this stock into penny land. IMHO I see this happening in 4-8 weeks hold time.
And it holds
And it holds :)
I agree with you here - asset accumulation news on dolomite should bring PPS over 1-2 pennies
Agreed!!!
Agree - but many members disagreed with me last Friday on the same. Personally I don't consider their 10q to be worse.
Not sure if anyone noticed - there was another uncompensated newsletter published on Saturday which was actually nice... From microcap daily
Agree but there were many here who expected very good rev
I guess from 10q filing
Must be 10q which was released on Friday night
1 billion in assets looks nice - but no one says how this math was arrived at , other than speculations. There is no link, but rest assured their dolomite Audit should give better figures than what was reported on 10q
How did you come to 1 billion dollar estimates ? Do you have numbers to substantiate your claims ?
I still do not get 1 billion revenues posted by others in this forum - I don't understand the math. Even considering dolomite market price and multiplying with what they estimate it to be.. Revenues from MJ on high side would be 10-30 million or so - assuming they get new growers in next few months ..
CGRA doesn't get revenues from pot sales.
Lots of misinformation here - check my previous post.
From the response of jbem - The Mayo Clinic is funding everything. Everything has been set up and the Mayo clinic is covering all the cost. When you have cutting edge molecules, that's what happens.
Buyinit,
As I understand the news, they have around 15 'available' offices that could be used by different licensees to grow pot... Even assuming 40 million dollar revenues from it - on high side. Now a billion dollar revenue , i.e, 960 million dollar revenues - are you stating majority of this is going to come from dolomite reserve value ? I do not understand this part, because they put 10 million or so under dolomite reserve in form 10q last week.. Can you clarify this with figures? Appreciate it mate.
Jbem - what are your thoughts on ER? Did you see anything that is not in sync with your expectations? I went through it in detail, my take is that this ER is ok, but will not make stock jump up, however I am closely watching ASCO presentation on May 29-31 in Chicago - that could be a big catalyst for this stock to touch .40 levels... Agree?
Also what charting software do you guys use? I currently use tc2000 because I like newsfeed as well.... For level 2 I use ihub
Hi I am new to this group... lil about myself- Entered trading stock start of 2015.... So far break even trade for me... Mostly look into 2-3 indicators from technical perspective, but reading 123tom's detailed description on pump and dump, I am taking next step to be a tech savvy... I can understand basics but nothing technical , but I am quick learner...
Wanted to hear from you all - what are the technical indicators you use to study the charts ?
I am currently learning Elliot wave and ichimoku cloud .... Taking notes and revisiting on charts I am trading at present - including TPIV SQNM etc.. HNR is another stock I am watching now - because I do not see any fundamentals making a stock like HNR run more than 100% in couple of days - so seeing technical angles....
Macd
Bb
Rsi
Mean average
Elliot cloud
Ichimoku
Do I need to add more indicators ?
I personally didn't expect revenues this q1.... I have told about this before....however I guess next quarter is going to be game changer... I will add positions when price pulls back
Btw CGRA just release 10q lol - expecting pull back on Monday lol - I will add when it pulls back :)
Dolomite reserves is not completely audited and wouldn't account when doing q1 reporting - I have talked about this earlier today
They would appear in q2 revenues not q1.... That's what I was saying little b4. I would say this is not bad fin report..
Thanks, are you there only in ihub - is ihub the best place to reach out to you or follow you so that I can get the best from you ?
Any suggestions mate ? I do not hold big account or something - just cash account - seeing and hunting for opportunities. No blame games intended :)
Me too - been trading only for last 4 months lol... But I do read a lot and inspect a lot lol
No worries man... I read your other post on pumpers and ... And I sometimes look at other part - fundamentals - lol like share structure and connect with investor.. And basic charting indicators in general... At some point I will do more intense charting tools you have put lol
Thank you.... Wasn't able to confirm handle - I see a small handle formed in 2 weeks.. And I saw volume - thanks for confirming
TPIV - current state of company
TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. The Company now has multiple clinical trials underway at the Mayo Clinic in Rochester, MN. In addition to our own sponsored clinical trials, a new grant-funded breast and ovarian cancer trial was started by Mayo using the same Folate Alpha Receptor peptides to which we have the exclusive commercial rights. Our development pipeline is extremely strong and provides us the opportunity to continue to expand on collaborations with leading institutions and corporations.
In Q1 2015, we strengthened our balance sheet by raising additional $2.5M in working capital giving us confidence in our ability to continue developing our products on the path to commercialization. The structure of this financing gives us additional opportunities to raise additional capital through the exercise of short-term and long-term warrants. The strength of our science and development approaches is becoming more widely appreciated, particularly as our clinical program has now generated positive interim data on both clinical programs in Breast and Ovarian Cancer. Also, we are pleased to report that our clinical programs are seeing positive outcomes and we expect further read outs on the data as we approach the annual ASCO meeting (Association of Clinical Oncology) in Chicago at the end of May.
We continue to be focused on our entry into Phase II Triple Negative Cancer Trials including application for Fast Track & Orphan Drug Status as well as planning for Phase II HER2/neu Breast Cancer Trials.
We will also produce new PolyStart™ constructs, in-house, to facilitate collaborative efforts in our current clinical indications and those where others have already indicated interest in combination therapies.
In addition, we will continue to work on deficit reduction and capital improvement in order to make the required benchmarks for an uplisting to the NASDAQ. To that end we are also anticipating the result of grant applications submitted early this year.
Together, these fundamental programs and corporate activities have positioned TapImmune extremely well to capitalize on the acceptance of immunotherapy as a leading therapeutic strategy in cancer and infectious disease resulting in exploding valuations in the market.
TapImmune’s Pipeline
The Company has a deep pipeline of potential blockbuster immunotherapies under development. Two of the clinical programs are completing Phase I studies and are expected to advance to Phase II in 2015. These are major inflection and valuation events, and we believe that, in light of these assets, the Company is significantly undervalued. Over the past year a number of highly visible transactions and billion dollar acquisitions have taken place that validate the work we are doing. We believe that, if our treatment successfully reaches commercialization, our treatment is applicable to 50% of the HER2/neu Breast Cancer market, which is a $21 billion annual market. We further believe that if our Ovarian Cancer treatment reaches commercialization, it will be applicable to 95% of the market which Decision Resources, one of the world’s leading research firms for pharmaceuticals and healthcare, believes will triple in the next 10 years to at least $1.5 billion annually.
In addition to the exciting clinical developments, our peptide vaccine technology may be coupled with our recently developed in-house Polystart™ nucleic acid-based technology designed to make vaccines significantly more effective by producing four times the required peptides for the immune systems to recognize and act on. Our nucleic acid-based systems can also incorporate “TAP” which stands for Transporter associated with Antigen Presentation. Our technologies are also widely applicable to the treatment of emerging viral threats and pandemics. In particular, our highly versatile PolyStart™ technology has application in these areas. With respect to validation of our technologies, it is important to note that the majority of our technologies have been published in leading peer-reviewed journals. The timing of such publications is consistent with the filing of patents.
Impressed reading the article..
If this breaks .090 with bigger volume that today expect this stock to touch .12 - .125 in couple of days... I can smell breakout coming in 2-3 trading days.
I started following you and reading more about charting especially on TVIP. I am currently in another stock CGRA. Would you care to comment if this chart has ingredients on cup and handle ? I am no expert but when I have free time I draw various patterns..
posimg.org/image/8qenmflk7/
CGRA updated chart - I do not think so it would pull back unless ER is very bad or if there is some other catalyst...Looks like CGRA have right ingredients for break out - cup and handle pattern.. refer to chart below...
http://postimg.org/image/8qenmflk7/